Tactile Systems Technology stock
TCMDNASDAQTactile Systems Technology, Inc., HealthcareISIN US87357P1003
68Score 68 out of 100, Neutral
Price and trend
67 / 100
Price history
+9.1% in one yearThe chart shows daily closes over 10 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 4.3% above it.
Since September 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 67).
The price is 19% below its 52-week high. Largest decline in 10 years: 91% (February 2019 to June 2022).
Chart figures for advanced users
- SMA 50$23.26
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$25.70
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)67
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$21.71
- The lowest closing price of the last twelve months.
- Resistance$33.05
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Tactile Systems Technology, Inc. belongs to the Medical (Devices) industry (United States) and, with a market value of $600.81M, is number 76 of 88 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $329.52M (up 12.5% year on year) and earnings of $19.09M (up 12.5%).
- For fiscal 2026, analysts expect on average revenue of $362.51M (up 10%) and adjusted earnings per share of $1.13 (up 36.1%).
Show more
- MEQIRI Score 68 out of 100 (Neutral): rank 169 of 702 in Healthcare, median 53.
- The P/E is 26 (Medical (Devices) median 29.1, own median of recent years 85.2).
- Our model puts fair value at $27.72, with the price 3% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $75.11M, financial debt $17.07M.Stability 78
- Analysts expect strong earnings growthUp 20.7% a year through 2027 (estimates from 2 analysts).Growth 74
- Earnings turn into cashFree cash flow 122% of earnings over the last 12 months.Fundamentals 72
Weaknesses
- DilutionShare count up 18% since 2020.Capital allocation 42
- Volatile share priceVolatility 49% a year over the last 12 months.
Its standout strengths are stability and momentum, while capital allocation holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $19.80 and expensive above $46.20 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $25.41 (cash-flow model) and $30.03 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $25.68, at 7.8% it would be $30.78.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (29.1).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 14.4% on the twelve months before. Revenue has grown strongly since 2013, at around 20% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 75%, operating 9%, net 6%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 16 Feb 2027in 95 days
- Last reported
- 2 Nov 2026EPS reported $0.31 (expected $0.28)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $1.13+1.2%
- Revenue
- $362.51M0.0%
- Earnings per share
- $1.50−2.4%
- Revenue
- $396.73M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −18.1%2026 revenue guidance updated to $360 to $366 million (growth of 9% to 11%), lymphedema still low double digit and airway clearance now about flat; the company did not state the direction versus earlier.
“For the full year 2026, we are updating your guidance and now expect total revenue in the range of $360 million to $366 million, representing growth of approximately 9% to 11% year-over-year.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 10 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $578,243 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Tactile Systems Technology
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 68
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Xvivo PerfusionXVIVO.ST $640.54M50
- Pacific Biosciences of CaliforniaPACB $612.34M35
- Sight SciencesSGHT $610.81M48
- MedistimMEDI.OL $604.15M81
- Anteris Technologies GlobalAVR $571.11M33
- Ion Beam ApplicationsIBAB.BR $555.09M58
- Avita MedicalRCEL $500.03M47
- CellaVisionCEVI.ST $483.11M80
ETFs that hold Tactile Systems Technology
Held by 3 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.06% | 0.30% | €185.82M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.02% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.02% | 0.30% | €2.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 8 Nov 2024)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.